¼¼°èÀÇ ³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú(ERCP) ½ÃÀå
Endoscopic Retrograde Cholangiopancreatography
»óǰÄÚµå : 1791666
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 183 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License)
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)


Çѱ۸ñÂ÷

¼¼°èÀÇ ³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú(ERCP) ½ÃÀåÀº 2030³â±îÁö 75¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 47¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú(ERCP) ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 8.3%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 75¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ³»½Ã°æÀº CAGR 9.6%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 29¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ³»½Ã°æ Ä¡·á ±â±â ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 8.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 12¾ï ´Þ·¯, Áß±¹Àº CAGR 8.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú(ERCP)½ÃÀåÀº 2024³â¿¡ 12¾ï ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 12¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 8.0%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 7.8%¿Í 6.9%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 6.5%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú(ERCP) ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ERCP°¡ ¼ÒÈ­±â ¹× °£´ãÃéÀå ÀÇ·á¿¡¼­ Áß¿äÇÑ ½Ã¼úÀÎ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú(ERCP)Àº ´ã¼®, ´ã°ü ÇùÂø, ÃéÀå Á¾¾ç, ¸¸¼º ÃéÀå¿° µî ´ãµµ ¹× ÃéÀå ÁúȯÀÇ Áø´Ü ¹× Ä¡·á¿¡ »ç¿ëµÇ´Â Àúħ½ÀÀû ³»½Ã°æ ±â¼úÀÔ´Ï´Ù. ÀÌ ½Ã¼úÀº ³»½Ã°æ °Ë»ç¿Í Åõ½Ã °Ë»ç¸¦ °áÇÕÇÏ¿© ´ãµµ ¹× Ãé°ü¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â º´º¯À» °¡½ÃÈ­ÇÏ¿© Ä¡·áÇÏ´Â °ÍÀ¸·Î, °³º¹ ¼ö¼úÀÇ Çʿ伺À» ÁÙ¿©ÁÝ´Ï´Ù.

´ã³¶Áúȯ, ÃéÀå¾Ï, ´ã°üÆó¼âÀÇ À¯º´·ü Áõ°¡¿Í °£´ãµµ°è Áúȯ¿¡ Ãë¾àÇÑ ³ë·ÉÀα¸ Áõ°¡·Î ÀÎÇØ ERCP ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÚ°¡ÆØÃ¢Çü ±Ý¼Ó ½ºÅÙÆ®(SEMS), °ý¾à±Ù Àý°³±â, dz¼± È®Àå±â µî ERCP ¾×¼¼¼­¸®ÀÇ ¹ßÀüÀ¸·Î ½Ã¼ú ¼º°ø·ü°ú ȯÀÚ ¿¹Èİ¡ °³¼±µÇ°í ÀÖ½À´Ï´Ù. º´¿ø°ú Àü¹® ¼ÒÈ­±â¼¾ÅͰ¡ ³»½Ã°æ ±â´ÉÀ» È®´ëÇÔ¿¡ µû¶ó ERCPÀÇ µµÀÔÀº ´õ¿í È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ERCP ±â¼úÀÇ ÃֽŠÇõ½ÅÀ̶õ?

ÃÖ±Ù ERCPÀÇ ¹ßÀüÀº ½Ã°¢È­ °­È­, ÇÕº´Áõ °¨¼Ò, Ä¡·á Á¤È®µµ Çâ»ó¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. °íÈ­Áú µðÁöÅÐ Åõ½Ã¹ý°ú AI Áö¿ø ´ã°üÁ¶¿µ¼ú ÇØ¼®ÀÇ °³¹ß·Î ÀÛÀº º´º¯°ú ´ã°ü ÀÌ»ó ¹ß°ßÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÃÖ÷´Ü ´ã°ü°æ Ç÷§ÆûÀÎ SpyGlass Direct Visualization Systems´Â ´ã°ü ¹× Ãé°üÀÇ ½Ç½Ã°£ ¿µ»óÈ­, Ç¥ÀûÈ­µÈ »ý°Ë äÃë ¹× Á¤¹Ð °¡À̵å ÇÏ °á¼® Á¦°Å¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

»ýºÐÇØ¼º ´ãµµ ½ºÅÙÆ®ÀÇ µµÀÔÀ¸·Î Àç¼ö¼úÀÇ Çʿ伺ÀÌ °¨¼ÒÇϰí, ȯÀÚÀÇ ÆíÀǼºÀÌ Çâ»óµÇ¾úÀ¸¸ç, ÀÇ·áºñ¿ëÀÌ Àý°¨µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ½Ã¼úÀÇ Á¤È®µµ¸¦ ³ôÀ̰í, ½Ã¼úÀÚÀÇ ÇǷθ¦ ÁÙÀ̸ç, º¹ÀâÇÑ ´ãµµ ¹× ÃéÀå ÁúȯÀÇ Ä¡·á ¼ºÀûÀ» Çâ»ó½Ã۱â À§ÇØ ·Îº¿ º¸Á¶ ERCP ±â¼úÀÌ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù. ERCP°¡ °è¼Ó ÁøÈ­Çϰí ÀÖ´Â °¡¿îµ¥, ¸Ó½Å·¯´× ±â¹Ý ¿¹Ãø ºÐ¼®°ú AI °¡ÀÌµå ³»½Ã°æ ³»ºñ°ÔÀ̼ÇÀÇ ÅëÇÕÀ¸·Î ½Ã¼úÀÇ Á¤È®¼º°ú ¾ÈÀü¼ºÀÌ Çâ»óµÉ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

ERCP ½ÃÀåÀÇ ¼ºÀåÀ» À̲ô´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

ERCP ½ÃÀåÀÇ ¼ºÀåÀº ¼ÒÈ­±â Áúȯ Áõ°¡, ÃÖ¼Ò Ä§½ÀÀû ±â¼úÀÇ Ã¤Åà Áõ°¡, ³»½Ã°æ ¿µ»ó ¹× ÁßÀç µµ±¸ÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ´ãµµ ¹× ÃéÀå Áúȯ¿¡ ´ëÇÑ ºñ¼ö¼úÀû Ä¡·á¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼­ °í±Þ ³»½Ã°æ ¼¾ÅÍÀÇ È®´ë¿Í ÇÔ²² ½ÃÀå ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÃéÀå¾Ï ¹ßº´·ü Áõ°¡¿Í Ä¡·áÀû ³»½Ã°æ ½Ã¼úÀÇ Çʿ伺ÀÌ Áõ°¡Çϸ鼭 ERCPÀÇ µµÀÔ¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

Â÷¼¼´ë ERCP Àåºñ, AI žÀç ´ã°ü°æ Ç÷§Æû, ·Îº¿ º¸Á¶ ³»½Ã°æÀÇ ÅëÇÕ¿¡ ´ëÇÑ ±ÔÁ¦ ½ÂÀÎÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í °¡¼ÓÈ­ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀü, ÇコÄɾî ÅõÀÚ Áõ°¡, Àü¹® ¼ÒÈ­±â ÀÇ·á¿¡ ´ëÇÑ Àü ¼¼°è Á¢±Ù¼º Áõ°¡·Î ÀÎÇØ ERCP ½ÃÀåÀº ÇâÈÄ ¸î ³â µ¿¾È Å©°Ô È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

Á¦Ç°(³»½Ã°æ, ³»Ä¡·á ÀåÄ¡, ½Ã°¢È­ ½Ã½ºÅÛ, ¿¡³ÊÁö ÀåÄ¡, ±âŸ); ½Ã¼ú(´ãµµ °ý¾à±Ù Àý°³¼ú, ´ãµµ ½ºÅÙÆ®, ´ãµµ È®Àå¼ú, ÃéÀå °ý¾à±Ù Àý°³¼ú, Ãé°ü ½ºÅÙÆ®, Ãé°ü È®Àå¼ú); ÃÖÁ¾ ¿ëµµ(º´¿ø, ¿Ü·¡ ȯÀÚ ½Ã¼³)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Endoscopic Retrograde Cholangiopancreatography Market to Reach US$7.5 Billion by 2030

The global market for Endoscopic Retrograde Cholangiopancreatography estimated at US$4.7 Billion in the year 2024, is expected to reach US$7.5 Billion by 2030, growing at a CAGR of 8.3% over the analysis period 2024-2030. Endoscopes, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Endotherapy Devices segment is estimated at 8.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 8.0% CAGR

The Endoscopic Retrograde Cholangiopancreatography market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.8% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Market - Key Trends & Drivers Summarized

Why Is ERCP a Critical Procedure in Gastrointestinal and Hepatobiliary Medicine?

Endoscopic Retrograde Cholangiopancreatography (ERCP) is a minimally invasive endoscopic technique used for the diagnosis and treatment of biliary and pancreatic disorders, including gallstones, bile duct strictures, pancreatic tumors, and chronic pancreatitis. This procedure combines endoscopy and fluoroscopy to visualize and treat conditions affecting the biliary and pancreatic ducts, reducing the need for open surgical interventions.

The rising prevalence of gallbladder disease, pancreatic cancer, and bile duct obstructions, along with increasing geriatric populations prone to hepatobiliary disorders, has significantly increased the demand for ERCP procedures. Additionally, advancements in ERCP accessories, including self-expanding metal stents (SEMS), sphincterotomes, and balloon dilators, have improved procedural success rates and patient outcomes. As hospitals and specialty gastroenterology centers expand their endoscopic capabilities, ERCP adoption is expected to grow further.

What Are the Latest Innovations in ERCP Technology?

Recent advancements in ERCP have focused on enhancing visualization, reducing complications, and improving therapeutic precision. The development of high-definition digital fluoroscopy and AI-assisted cholangiography interpretation has improved the detection of small lesions and bile duct abnormalities. SpyGlass Direct Visualization Systems, a state-of-the-art cholangioscopy platform, allows real-time imaging of bile and pancreatic ducts, enabling targeted biopsy collection and precision-guided stone removal.

The introduction of biodegradable biliary stents has reduced the need for repeat procedures, improving patient convenience and lowering healthcare costs. Additionally, robot-assisted ERCP techniques are being explored to enhance procedural precision, reduce operator fatigue, and improve outcomes in complex biliary and pancreatic disorders. As ERCP continues to evolve, the integration of machine learning-based predictive analytics and AI-guided endoscopic navigation is expected to enhance procedural accuracy and safety.

What Is Driving the Growth of the ERCP Market?

The growth in the ERCP market is driven by rising gastrointestinal disorders, increased adoption of minimally invasive techniques, and advancements in endoscopic imaging and intervention tools. The growing preference for non-surgical treatments for biliary and pancreatic diseases, combined with the expansion of advanced endoscopy centers, has fueled market demand. Additionally, the rise in pancreatic cancer incidence and the increasing need for therapeutic endoscopic procedures have contributed to ERCP adoption.

Regulatory approvals for next-generation ERCP devices, AI-powered cholangioscopy platforms, and the integration of robotic-assisted endoscopy are expected to further accelerate market growth. With continued technological advancements, rising healthcare investments, and increasing global access to specialized gastroenterology care, the ERCP market is poised for substantial expansion in the coming years.

SCOPE OF STUDY:

The report analyzes the Endoscopic Retrograde Cholangiopancreatography market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices, Others); Procedure (Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation, Pancreatic Sphincterotomy, Pancreatic Duct Stenting, Pancreatic Duct Dilation); End-Use (Hospitals, Outpatient Facilities)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â